Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00053950 · ClinicalTrials.gov registry record · Phase 1
Pyrazoloacridine and Stem Cell or Bone Marrow Transplantation in Treating Young Patients With High-Risk Neuroblastoma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT00053950: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00053950 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00053950, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of pyrazoloacridine given together with peripheral stem cell or bone marrow transplantation in treating young patients with high-risk neuroblastoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell or bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.
Interventions
- OTHER laboratory biomarker analysis
- PROCEDURE peripheral blood stem cell transplantation
- BIOLOGICAL filgrastim
- DRUG pyrazoloacridine
- PROCEDURE autologous bone marrow transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2002-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00053950
The ClinicalTrials.gov registry entry for NCT00053950 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00053950 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00053950 about?
NCT00053950 is a clinical study titled "Pyrazoloacridine and Stem Cell or Bone Marrow Transplantation in Treating Young Patients With High-Risk Neuroblastoma". This phase I trial is studying the side effects and best dose of pyrazoloacridine given together with peripheral stem cell or bone marrow transplantation in treating young patients with high-risk neuroblastoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they s...
What is the current status of trial NCT00053950?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2002-12.
What interventions are being tested in trial NCT00053950?
The interventions under investigation include: laboratory biomarker analysis (OTHER), peripheral blood stem cell transplantation (PROCEDURE), filgrastim (BIOLOGICAL), pyrazoloacridine (DRUG), autologous bone marrow transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00053950?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.